BioCorRx Inc. (BICX)

BioCorRx Inc. (BICX) Healthcare & Pipeline Overview

BioCorRx Inc. is a U.S.-based healthcare company specializing in substance abuse and weight management treatments. It offers the BioCorRx recovery program with a proprietary naltrexone implant and the UnCraveRx weight loss program, alongside developing injectable and implantable naltrexone products for addiction and alcoholism. The company targets healthcare providers.

What Is the Investment Thesis for BICX?

BioCorRx Inc. operates within critical healthcare segments, focusing on substance abuse and weight management, markets characterized by significant unmet needs and growing demand. The company's investment thesis centers on its proprietary BioCorRx recovery program, which leverages a non-addictive naltrexone implant coupled with counseling, offering a differentiated approach to addiction treatment. The UnCraveRx weight loss program further diversifies its revenue streams by addressing another prevalent health challenge through medically assisted methods. A key value driver is the company's development pipeline, specifically BICX101 (injectable naltrexone) and BICX104 (implantable naltrexone), which represent potential future growth catalysts upon successful clinical development and regulatory approval. The company's current financial profile, including a gross margin of 84.0%, indicates strong unit economics for its existing programs. However, a profit margin of -391.2% highlights the significant operational costs and R&D investments relative to its current revenue, typical for a development-stage healthcare company with a small operational footprint of three employees. Investors would consider the potential for pipeline commercialization and expanded program adoption to drive future profitability, balancing this against the inherent risks of clinical development, regulatory hurdles, and market acceptance in competitive healthcare sectors.

Based on FMP financials and quantitative analysis

BICX Key Highlights

• BioCorRx Inc. maintains a high gross margin of 84.0%, indicating strong profitability on its core program offerings.
• The company operates with a market capitalization of $8.35M, reflecting its current valuation as a micro-cap entity in the healthcare sector.
• A significant negative profit margin of -391.2% points to substantial ongoing operational expenses and investments, likely associated with R&D and program development.
• BioCorRx Inc. exhibits a low Beta of 0.14, suggesting its stock price has historically shown less volatility compared to the broader market.
• The company does not currently pay a dividend, consistent with its focus on reinvesting capital into growth and product development.

Who Are BICX's Competitors?

BICX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BICX's Key Strengths?

• Proprietary naltrexone implant and integrated counseling program for substance abuse.
• High gross margin of 84.0% on existing programs, indicating strong unit economics.
• Diversified offerings in both substance abuse and weight management with UnCraveRx.
• Development pipeline with two naltrexone-based products (BICX101, BICX104) for future growth.

What Are BICX's Weaknesses?

• Significant negative profit margin of -391.2%, indicating unprofitability.
• Small employee count of 3, potentially limiting operational scale and R&D capacity.
• Reliance on naltrexone-based treatments, which may face market competition or evolving treatment paradigms.
• Products in development (BICX101, BICX104) are subject to regulatory approval and market acceptance risks.

What Could Drive BICX Stock Higher?

• Potential positive clinical trial results or regulatory milestones for BICX101, the injectable naltrexone product, advancing it closer to commercialization.
• Potential positive clinical trial results or regulatory milestones for BICX104, the implantable naltrexone implant, progressing its development pathway.
• Expansion of the BioCorRx recovery program's licensing and distribution network to new healthcare providers and clinics across the United States.
• Increased adoption and enrollment in the UnCraveRx weight loss management program, driving revenue growth through broader market penetration.

What Are the Key Risks for BICX?

• Significant negative profit margin of -391.2%, indicating the company is not currently profitable and requires substantial operational funding.
• Regulatory approval risks for pipeline products BICX101 and BICX104, which could face delays or failure to obtain necessary clearances.
• Intense competition within the substance abuse treatment and weight management markets from established players and new entrants.
• Funding challenges for ongoing research and development, as well as general operations, given the company's financial profile and small employee base.
• Market acceptance and adoption rates of BioCorRx's proprietary programs and future products may be lower than anticipated.

What Are the Growth Opportunities for BICX?

• Growth opportunity 1: Expansion of the BioCorRx Recovery Program. The company's proprietary naltrexone implant coupled with counseling addresses a critical need in the substance abuse treatment market. With ongoing opioid and alcohol addiction crises, the demand for non-addictive, medication-assisted treatments is substantial. Expanding the licensing and distribution network to more healthcare providers and independent clinics across the U.S. represents a significant growth driver. This involves increasing outreach, provider training, and demonstrating clinical efficacy to capture a larger share of the addiction treatment market, which is projected to continue growing over the next decade as awareness and acceptance of MATs increase. The focus on a comprehensive, integrated approach can enhance patient outcomes and program adoption.
• Growth opportunity 2: Broadening the reach of the UnCraveRx Weight Loss Management Program. The medically assisted weight management market is experiencing significant expansion, driven by rising obesity rates and a greater emphasis on health and wellness. UnCraveRx, combining medication to reduce cravings with virtual lifestyle support, fitness, and nutrition, positions BioCorRx to capitalize on this trend. Increasing marketing efforts, forming partnerships with employers or health systems, and enhancing the virtual support platform can accelerate program enrollment. The convenience of on-demand virtual support makes it accessible to a wider demographic, potentially expanding market penetration and revenue streams over the next 3-5 years as demand for flexible health solutions grows.
• Growth opportunity 3: Commercialization of BICX101, an injectable naltrexone product. The development of BICX101 represents a significant pipeline opportunity for BioCorRx Inc. Injectable naltrexone formulations are a well-established modality for treating opioid and alcohol dependence, offering sustained release and improved adherence compared to oral medications. Successfully navigating the clinical trial process and securing regulatory approvals (e.g., FDA) for BICX101 would allow BioCorRx to enter a larger segment of the medication-assisted treatment market. This could significantly expand the company's addressable market and revenue potential within the next 3-7 years, leveraging existing relationships with healthcare providers for distribution.
• Growth opportunity 4: Commercialization of BICX104, an implantable naltrexone implant. Similar to BICX101, the development and eventual commercialization of BICX104, another implantable naltrexone product, offers substantial growth potential. An implantable formulation could provide long-term, continuous drug delivery, potentially improving patient compliance and treatment outcomes for opioid addiction and alcoholism. This product could differentiate BioCorRx further in the MAT landscape by offering an alternative to daily oral medications or monthly injections. Successful development and regulatory clearance of BICX104 over the next 5-10 years would position the company with a unique, long-acting treatment option, potentially commanding a premium in the specialized addiction treatment market.
• Growth opportunity 5: Expansion of the distribution network and strategic partnerships. BioCorRx Inc. currently distributes its programs to healthcare providers, independent licensed clinics, and licensed healthcare professionals. A key growth opportunity lies in strategically expanding this network, potentially through partnerships with larger healthcare organizations, national clinic chains, or government-funded programs. Such expansion could significantly increase patient access to both the BioCorRx recovery program and UnCraveRx, as well as future pipeline products. Developing robust training and support for new partners can ensure consistent program delivery and foster deeper market penetration, driving revenue growth over the medium term (2-5 years).

What Opportunities Does BICX Have?

• Expanding market demand for non-addictive substance abuse treatments and medication-assisted weight management.
• Successful commercialization of pipeline products BICX101 and BICX104, opening new revenue streams.
• Expansion of distribution network through partnerships with larger healthcare organizations or clinic chains.
• Leveraging virtual support models (UnCraveRx) to reach a broader patient demographic.

What Threats Does BICX Face?

• Intense competition from established pharmaceutical companies and other treatment providers in both sectors.
• Regulatory hurdles and potential delays in obtaining approvals for pipeline products.
• Funding challenges for ongoing research and development, given the current financial profile.
• Market acceptance and adoption rates of proprietary programs and new products.

What Are BICX's Competitive Advantages?

• Proprietary naltrexone implant for the BioCorRx recovery program, offering a unique delivery mechanism.
• Non-addictive, medication-assisted treatment approach for substance abuse, differentiating from certain other MATs.
• Integrated counseling component with the BioCorRx program, providing a holistic treatment model.
• Development pipeline with BICX101 and BICX104, representing potential future proprietary products.
• Combination of medically assisted treatment with virtual lifestyle support for the UnCraveRx program.

What Does BICX Do?

BioCorRx Inc., headquartered in Anaheim, California, operates through its subsidiaries to develop and deliver specialized treatment programs addressing substance abuse and related disorders across the United States. The company, which was formerly known as Fresh Start Private Management, Inc. before changing its name in January 2014, has evolved to focus on medication-assisted treatment. Its flagship offering is the BioCorRx recovery program, a non-addictive, comprehensive treatment that integrates a structured counseling program with its proprietary naltrexone implant. This program is designed to support individuals in overcoming addiction by reducing cravings and blocking opioid receptors, providing a unique approach to long-term recovery. Beyond substance abuse, BioCorRx Inc. has diversified its portfolio to include the UnCraveRx weight loss management program. This program combines medically assisted weight management techniques, specifically targeting the reduction of food cravings, with a robust support system that includes on-demand virtual lifestyle coaching, fitness guidance, and nutritional advice. The company's strategic vision also encompasses a robust development pipeline. Currently, BioCorRx Inc. is advancing BICX101, an injectable naltrexone product, and BICX104, an implantable naltrexone implant. Both products are specifically being developed for the treatment of opioid addiction and alcoholism, aiming to expand the company's proprietary offerings and reach a broader patient population. BioCorRx Inc. primarily distributes its programs and future products to a network of healthcare providers, independent licensed clinics, and licensed healthcare professionals, establishing a B2B model for market penetration and patient access.

What Products and Services Does BICX Offer?

• Develops and provides treatment programs for substance abuse and related disorders.
• Distributes and licenses the BioCorRx recovery program, a non-addictive, medication-assisted treatment.
• Offers a proprietary naltrexone implant as part of its BioCorRx recovery program.
• Integrates a counseling program with its naltrexone implant for comprehensive addiction treatment.
• Distributes the UnCraveRx weight loss management program, a medically assisted solution.
• Provides on-demand virtual lifestyle support, fitness, and nutrition with UnCraveRx.
• Develops BICX101, an injectable naltrexone product for opioid addiction and alcoholism.
• Develops BICX104, an implantable naltrexone implant for opioid addiction and alcoholism.

How Does BICX Make Money?

• Licenses the BioCorRx recovery program to healthcare providers and clinics.
• Distributes its proprietary naltrexone implant as part of the BioCorRx recovery program.
• Distributes the UnCraveRx weight loss management program, likely through direct sales or subscriptions to clinics and individuals.
• Generates revenue from sales of its programs and potentially from future sales of pipeline products like BICX101 and BICX104 upon commercialization.

What Industry Does BICX Operate In?

BioCorRx Inc. operates within the 'Medical - Care Facilities' industry, specifically targeting the broader healthcare sector's substance abuse treatment and weight management markets. The substance abuse treatment market is driven by rising addiction rates and increasing awareness of medication-assisted treatments (MATs). BioCorRx's non-addictive naltrexone implant positions it within a niche seeking alternatives to opioid-based MATs. Concurrently, the weight management market is experiencing robust growth due to rising obesity rates and demand for medically supervised programs. BioCorRx's UnCraveRx program competes in this space by combining medication with lifestyle support. The competitive landscape includes pharmaceutical companies developing addiction medications, specialized clinics, and a growing number of digital health platforms for weight loss. BioCorRx differentiates itself through its proprietary naltrexone implant and integrated counseling, as well as its comprehensive approach to weight management, aiming to capture market share by offering distinct, medically-assisted solutions.

Who Are BICX's Key Customers?

• Healthcare providers seeking substance abuse treatment solutions.
• Independent licensed clinics offering addiction and weight management services.
• Licensed healthcare professionals looking for specialized treatment programs.
• Patients seeking non-addictive substance abuse treatment or medically assisted weight management.

Company Profile

BioCorRx Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Anaheim, US. The company is led by CEO Lourdes Felix. BICX has traded publicly since 2010.

BioCorRx Inc. Financial Trajectory

BioCorRx Inc. (BICX) reported $215K in revenue for Q1 2026, a decline of 66.2% compared to the prior quarter. The company recorded a net loss of $831K, with diluted EPS of $-0.03. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare.

How BioCorRx Inc. Is Valued

BioCorRx Inc. carries a market capitalization of $8.35M, placing it in the micro-cap category. Relative to its peer group, BICX's quantitative score of 52/100 is roughly in line with the peer average of 61/100.

ROE 28%Key Financial Metrics

Return on equity for BioCorRx Inc. stands at 28.1%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -29.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.12 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -40.6%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 4/9Financial Health

BioCorRx Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.

FY2026 estForward Outlook

Wall Street analysts project BioCorRx Inc. revenue of about $972K for fiscal 2026, with EPS near $-0.21.

BICX Financials

BICX Latest News

No recent news available for BICX.

BICX Analyst Consensus

BICX MoonshotScore

BICX Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources